Sage Journals: Discover world-class research

Open access

Research article

First published 2021-9

Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis

Bruce AC Cree, Baldur Magnusson, Nicolas Rouyrre [...]

Multiple Sclerosis Journal

Open access

Research article

First published 2026

Positioning siponimod and the post-treatment gap: the unmet needs of SPMS patients in Italian real-world practice

Aurora Zanghì, Giovanna Borriello, Matteo Foschi [...]

Therapeutic Advances in Neurological Disorders

Open access

Research article

First published 2024-4

Real-world data on siponimod-related lymphopenia among people with secondary progressive multiple sclerosis

Christopher GS Gilmartin, Natasha Hoyle, Afagh Garjani [...]

Multiple Sclerosis Journal

Open access

Research article

First published 2021-10

Siponimod (BAF312) penetrates,distributes,and acts in the central nervous system: Preclinical insights

Marc Bigaud, Bettina Rudolph, Emmanuelle Briard [...]

Multiple Sclerosis Journal – Experimental,Translational and Clinical

Open access

Research article

First published 2022-9

Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years

Bruce AC Cree, Douglas L Arnold, Robert J Fox [...]

Multiple Sclerosis Journal

Open access

Research article

First published 2025-5

Safety and tolerability of conversion to siponimod from other disease-modifying therapies in patients with advancing forms of relapsing MS: Results from the EXCHANGE study

Robert J Fox, Stanley Cohan, Yang Mao-Draayer [...]

Multiple Sclerosis Journal

Open access

Research article

First published 2024-1

Onboarding of siponimod in secondary progressive multiple sclerosis patients in Australia: Novel,real-world evidence from the MSGo digital support programme

TA Hardy, P Aouad, MH Barnett [...]

Multiple Sclerosis Journal – Experimental,Translational and Clinical

Open access

Research article

First published 2022-9

Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial

Douglas L Arnold, Daniela Piani-Meier, Amit Bar-Or [...]

Multiple Sclerosis Journal

Open access

Research article

First published 2022

Assessing the immune response to SARS-CoV-2 mRNA vaccines in siponimod-treated patients: a nonrandomized controlled clinical trial (AMA-VACC)

Tjalf Ziemssen, Marie Groth, Benedict Rauser [...]

Therapeutic Advances in Neurological Disorders

Open access

Editorial

First published 2018

Prospects of siponimod in secondary progressive multiple sclerosis

Marisa McGinley, Robert J. Fox

Therapeutic Advances in Neurological Disorders

Search results